Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition

Immune checkpoint blockade has shown significant clinical benefit in multiple cancer indications, but many patients are either refractory or become resistant to the treatment over time. HER2/neu oncogene overexpressed in invasive breast cancer patients associates with more aggressive diseases and po...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Chang-ling, Zhu, Hai-xia, Deng, Lan, Meng, Xiao-qing, Li, Kai, Xu, Wei, Zhao, Le, Liu, Yue-qin, Zhu, Zhen-ping, Huang, Hao-min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888617/
https://www.ncbi.nlm.nih.gov/pubmed/33990766
http://dx.doi.org/10.1038/s41401-021-00683-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888617/
https://www.ncbi.nlm.nih.gov/pubmed/33990766
http://dx.doi.org/10.1038/s41401-021-00683-8

Ejemplares similares